{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:50:01Z","timestamp":1776185401276,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.autrev.2019.102453","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T13:55:48Z","timestamp":1576158948000},"page":"102453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review"],"prefix":"10.1016","volume":"19","author":[{"given":"Mattia","family":"Bellan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Patrucco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Barone-Adesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Gavelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi Mario","family":"Castello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Nerviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Cavagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Pirisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Paolo","family":"Sainaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2019.102453_bb0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","article-title":"Intertitial lung disease in connective tissue disorders","volume":"380","author":"Fischer","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2019.102453_bb0010","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2019.102453_bb0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.rmed.2017.03.028","article-title":"Clinical spectrum time course of interstitial pneumonia with autoimmune features in patients positive for antisynthetase antibodies","volume":"132","author":"Scir\u00e8","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0020","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004827","article-title":"Undiagnosed connective tissue diseases: high prevalence in pulmonary arterial hypertension patients","volume":"95","author":"Cavagna","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2019.102453_bb0025","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1148\/radiographics.22.suppl_1.g02oc04s151","article-title":"Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings","volume":"22","author":"Kim","year":"2002","journal-title":"Radiographics"},{"key":"10.1016\/j.autrev.2019.102453_bb0030","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2019.102453_bb0035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.114.3.801","article-title":"African-american race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease","volume":"114","author":"Greidinger","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2019.102453_bb0040","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.autrev.2016.07.025","article-title":"Pulmonary involvement in systemic sclerosis","volume":"15","author":"Morales-C\u00e1rdenas","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2019.102453_bb0045","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0050","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of myositis-related interstitial lung disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest."},{"key":"10.1016\/j.autrev.2019.102453_bb0055","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0000000000000434","article-title":"Clinical spectrum of anti-Jo-1-associated disease","volume":"29","author":"Monti","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.autrev.2019.102453_bb0060","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2019.102453_bb0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung."},{"key":"10.1016\/j.autrev.2019.102453_bb0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2019.102453_bb0075","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2019.102453_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001144","article-title":"AENEAS (American, European NEtwork of Antisynthetase syndrome) collaborative group. Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an International Retrospective Multicenter Study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2019.102453_bb0085","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","article-title":"Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review","volume":"13","author":"Mahler","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2019.102453_bb0090","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0272-5231(05)70113-1","article-title":"Respiratory complications in mixed connective tissue disease","volume":"19","author":"Prakash","year":"1998","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","article-title":"Primary Sj\u00f6gren syndrome in Spain: clinical and immunologic expression in 1010 patients","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2019.102453_bb0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2016.09.017","article-title":"Interstitial lung disease in primary Sj\u00f6gren\u2019s syndrome","volume":"16","author":"Roca","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2019.102453_bb0105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/ard.59.9.709","article-title":"Ten year follow up of pulmonary function in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"59","author":"Davidson","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2019.102453_bb0110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/1744666X.2018.1411190","article-title":"Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review","volume":"14","author":"Atzeni","year":"2018","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.autrev.2019.102453_bb0115","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0125","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.rmed.2009.02.009","article-title":"Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease","volume":"103","author":"Mittoo","year":"2009","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/rheumatology\/keq233","article-title":"The impact of rheumatological evaluation in the management of patients with interstitial lung disease","volume":"50","author":"Castelino","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102453_bb0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.autrev.2015.09.003","article-title":"Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature","volume":"15","author":"Ferri","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2019.102453_bb0140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MCP.0000000000000081","article-title":"Current approach to connective tissue disease-associated interstitial lung disease","volume":"20","author":"Solomon","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0034-1371531","article-title":"Immunosuppression for connective tissue disease-related pulmonary disease","volume":"35","author":"Maher","year":"2014","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0150","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3904\/kjim.2016.212","article-title":"Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist\u2019s point of view","volume":"32","author":"Koo","year":"2017","journal-title":"Korean J. Intern. Med"},{"key":"10.1016\/j.autrev.2019.102453_bb0155","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1378\/chest.12-0741","article-title":"Diagnosis and treatment of connective tissue disease-associated interstitial lung disease","volume":"143","author":"Vij","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2019.102453_bb0160","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4161\/mabs.26008","article-title":"Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics","volume":"5","author":"Golay","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2019.102453_bb0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2006.09.004","article-title":"Pharmacokinetics of rituximab and its clinical use: thought for the best use?","volume":"62","author":"Cartron","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.autrev.2019.102453_bb0170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0175","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.autrev.2019.102453_bb0185","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized double blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2019.102453_bb0195","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2019.102453_bb0200","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, doubleblind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2019.102453_bb0205","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2019.102453_bb0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0215","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000441238","article-title":"Treatment considerations of lung involvement in rheumatologic disease","volume":"90","author":"Robles-Pere","year":"2015","journal-title":"Respiration"},{"key":"10.1016\/j.autrev.2019.102453_bb0220","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","article-title":"Rituximab in the treatment of inflammatory myopathies: a review","volume":"56","author":"Fasano","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102453_bb0225","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","article-title":"Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review","volume":"17","author":"Thiebaut","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2019.102453_bb0230","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2019.102453_bb0235","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autrev.2019.102453_bb0240","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.autrev.2019.102453_bb0245","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102453_bb0250","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trial"},{"key":"10.1016\/j.autrev.2019.102453_bb0255","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modeification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.autrev.2019.102453_bb0260","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.autrev.2019.102453_bb0265","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17843286.2017.1372244","article-title":"Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis","volume":"73","author":"Melsens","year":"2018","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.autrev.2019.102453_bb0270","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2019.102453_bb0275","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000384","article-title":"Rituximab in early systemic sclerosis","volume":"3","author":"Boonstra","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2019.102453_bb0280","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2019.102453_bb0285","unstructured":"Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 2019; pii: annrheumdis-2018-214816."},{"key":"10.1016\/j.autrev.2019.102453_bb0290","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2019.102453_bb0295","first-page":"S181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34","author":"Lepri","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autrev.2019.102453_bb0300","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/RHU.0000000000000584","article-title":"Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease","volume":"23","author":"Sari","year":"2017","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.autrev.2019.102453_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- Synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2019.102453_bb0310","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102453_bb0315","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102453_bb0320","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated Antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2019.102453_bb0325","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2019.102453_bb0330","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/rheumatology\/kew195","article-title":"Rituximab in autoimmune connective tissue disease-associated interstitial lung disease","volume":"55","author":"Sharp","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102453_bb0335","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/resp.12214","article-title":"Rituximab in severe, treatment-refractory interstitial lung disease","volume":"19","author":"Keir","year":"2013","journal-title":"Respirology"},{"key":"10.1016\/j.autrev.2019.102453_bb0340","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2019.102453_bb0345","first-page":"1077","article-title":"Rituximab therapy in primary Sj\u00f6gren\u2019s syndrome with interstitial lung disease: a retrospective cohort study","volume":"34","author":"Chen","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autrev.2019.102453_bb0350","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Club Rhumatismes et inflammations and the French Society of Rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjogren\u2019s syndrome: results in 78 patients of the AutoImmune and rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2019.102453_bb0355","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of Sj\u00f6gren\u2019s syndrome: use of biologic agents, Management of Fatigue, and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.autrev.2019.102453_bb0360","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kex375","article-title":"British Society for Rheumatology standards, guideline and audit working group. The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren\u2019s syndrome","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102453_bb0365","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0961203313509295","article-title":"Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis","volume":"22","author":"Duxbury","year":"2013","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2019.102453_bb0370","doi-asserted-by":"crossref","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736\u201345.","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"10.1016\/j.autrev.2019.102453_bb0375","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2019.102453_bb0380","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2019.102453_bb0385","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MAJ.0b013e31818d094b","article-title":"Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects","volume":"337","author":"Saketkoo","year":"2009","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.autrev.2019.102453_bb0390","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/143637","article-title":"Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a metaanalysis","volume":"2012","author":"Tzouvelekis","year":"2012","journal-title":"Pulm. Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0395","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3899\/jrheum.121026","article-title":"Cyclosporine in anti-Jo1-positive patients with corticosteroidrefractory interstitial lung disease","volume":"40","author":"Cavagna","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2019.102453_bb0400","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0405","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ejim.2013.02.008","article-title":"Using cyclophosphamide in inflammatory rheumatic diseases","volume":"24","author":"Brummaier","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.autrev.2019.102453_bb0410","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","volume":"1","author":"Barnes","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.autrev.2019.102453_bb0415","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamaneurol.2017.3872","article-title":"New criteria needed for Antisynthetase syndrome","volume":"75","author":"Casta\u00f1eda","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.autrev.2019.102453_bb0420","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000784","article-title":"Idiopathic inflammatory myopathies: narrative review of unmet needs in clinical practice guidelines","volume":"4","author":"Meyer","year":"2019","journal-title":"RMD Open"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:17:02Z","timestamp":1761599822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219302666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1568997219302666"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102453","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102453"}}